NVS Jan 2025 90.000 put
| Previous Close | 1.0700 |
| Open | 1.0700 |
| Bid | 0.7500 |
| Ask | 1.1000 |
| Strike | 90.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 1.0700 - 1.0700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 307 |
ReutersNovartis, Roche unit and others face Italy antitrust probe over eye drug
ROME (Reuters) -Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis and Roche-controlled Genentech for having potentially restricted competition in the sale of an eye drug. Biopharma developer Samsung Bioepis, biotechs Biogen and Genentech, and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a drug made with ranibizumab and developed and sold by Samsung Bioepis, the watchdog said in a statement.
ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksNovartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
